The heterogeneity of viral bronchiolitis: A lack of universal consensus definitions

@article{Hancock2017TheHO,
  title={The heterogeneity of viral bronchiolitis: A lack of universal consensus definitions},
  author={David G Hancock and Billie Charles-Britton and Dani-Louise Dixon and Kevin D Forsyth},
  journal={Pediatric Pulmonology},
  year={2017},
  volume={52},
  pages={1234 - 1240}
}
Viral bronchiolitis is one of the most common hospital presentations in infancy and as such represents a major healthcare burden worldwide. However despite this, there are currently no effective targeted therapies nor can those infants at highest risk for developing severe disease or subsequent respiratory morbidity be predicted on initial hospital presentation. Current definitions of bronchiolitis in the published literature vary significantly in terms of the age range at presentation… Expand
The impact of viral bronchiolitis phenotyping: Is it time to consider phenotype-specific responses to individualize pharmacological management?
TLDR
New research is critically needed to refine viral bronchiolitis phenotyping at the molecular and clinical levels as well as to define phenotype-specific responses to different therapeutic options. Expand
Bronchiolitis clinics and medical treatment.
TLDR
The most controversial points in the management of bronchiolitis are discussed according to six evidence-based guidelines, six clinical practice guidelines and five consensus-based reviews. Expand
[Criteria heterogeneity in the diagnosis of acute bronchiolitis in Spain].
TLDR
Diagnostic criteria for AB in Spain are heterogeneous and strongly associated with their paediatric sub-specialty, which could cause variability in clinical practice with AB patients. Expand
Criteria heterogeneity in the diagnosis of acute bronchiolitis in Spain☆☆☆
TLDR
The diagnostic criteria for AB in Spain are heterogeneous and strongly associated with their paediatric sub-specialty, which could cause variability in clinical practice with AB patients. Expand
Overview of prevention and management of acute bronchiolitis due to respiratory syncytial virus
TLDR
Despite advances in preventative treatments, adherence to evidence-based guidelines provides the best prospect for successful reduction in morbidity and mortality. Expand
Time to Say Goodbye to Bronchiolitis, Viral Wheeze, Reactive Airways Disease, Wheeze Bronchitis and All That
TLDR
A proposed simplified approach to the nomenclature used to categorize virus associated LRTIs is presented based on an understanding of the underlying pathological processes and how these contribute to the physical signs. Expand
Maybe this is just asthma
  • B. Kuzik
  • Medicine
  • Pediatric pulmonology
  • 2017
TLDR
The apparent lack of bronchodilator response in bronchiolitis, and hence the dogmatic approach that this is not asthma, should remain open for debate. Expand
Immune biomarkers predicting bronchiolitis disease severity: A systematic review.
TLDR
The heterogeneity among included studies and the lack of a consistently significant biomarker highlight the need for consensus on bronchiolitis definitions and severity measures, as well as further studies assessing their clinical utility both in isolation and in combination. Expand
Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma
TLDR
Severe bronchiolitis caused by RV-A and RV-C was associated with earlier initiation and prolonged use of asthma control medication, and the risk was especially high when bronchiolaitis wasassociated with RV- C, atopic dermatitis, and fever. Expand
sRAGE as severe acute bronchiolitis biomarker, prospective observational study
Acute bronchiolitis (AB) is the leading cause of hospitalization in infants and around 5% require intensive care treatment. Early identification of children diagnosed with AB at a high risk of severeExpand
...
1
2
3
...

References

SHOWING 1-10 OF 62 REFERENCES
Viral bronchiolitis
TLDR
Evidence suggests no benefit from bronchodilator or corticosteroid use in infants with a first episode of bronchiolitis, and insufficient available data suggest a role for high-flow nasal cannula and continuous positive airway pressure use in a monitored setting to prevent respiratory failure. Expand
Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
TLDR
The strategies developed to fight RSV infection, the evidence for the use of palivizumab and a reasonable approach clinically and economically to the use is suggested, proposing its use selectively in the most vulnerable infants during the first six months of life. Expand
Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants
TLDR
Pharmacological prophylaxis with palivizumab for RSV bronchiolitis is indicated in specific categories of children at risk during the epidemic period, and may correlate with an increased incidence of recurrent wheezing in pre-schooled children and with asthma at school age. Expand
Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age.
TLDR
Groups at high risk for severe disease are described and guidelines for admission to hospital are presented, and evidence for the efficacy of various therapies is discussed and recommendations are made for management. Expand
A clustering approach to identify severe bronchiolitis profiles in children
TLDR
Several distinct clinical profiles (phenotypes) were identified by a clustering approach in two multicentre studies of children hospitalised for bronchiolitis, having important implications for future research on the aetiology, management and long-term outcomes of bronchiolaitis. Expand
Human metapneumovirus bronchiolitis in infancy is an important risk factor for asthma at age 5
TLDR
The aim of this study was to evaluate the outcome at third to fifth year after admission for hMPV‐bronchiolitis and to compare it with children admitted for respiratory syncytial virus (RSV), with children without lower respiratory disease in the first 2 years of life. Expand
Advancing our understanding of infant bronchiolitis through phenotyping and endotyping: clinical and molecular approaches
TLDR
Large cohort studies of bronchiolitis with comprehensive clinical characterization and system-wide profiling of the ‘-omics’ data should enhance the ability to molecularly understand these phenotypes and lead to more targeted and personalized approaches to bron chiolitis treatment. Expand
Bronchiolitis: Age and Previous Wheezing Episodes Are Linked to Viral Etiology and Atopic Characteristics
TLDR
In children with bronchiolitis, 2 clinical factors, age and number of previous wheezing episodes, are linked to inflammatory (atopy-related factors) and virologic risk factors of asthma (rhinovirus-associated disease). Expand
Recurrent wheezing and asthma after bocavirus bronchiolitis.
TLDR
Severe HBoV-bronchiolitis in infancy was strongly associated with asthma at 5-7 years and no differences were found with respect to allergic rhinitis, atopic dermatitis, food allergy, proportion of positive prick tests, and family history of atopy or asthma. Expand
Acute viral bronchiolitis: Physician perspectives on definition and clinically important outcomes
TLDR
This work assessed how paediatricians and general practitioners perceived definition and clinically important outcomes in bronchiolitis and the heterogeneous choice of outcome measures in current clinical trials. Expand
...
1
2
3
4
5
...